Scarica l'app Stockscreener
5.58
4.78%
-0.28
Pre-mercato:
5.69
0.11
+1.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.86
Aprire:
$5.86
Volume 24 ore:
199.07K
Relative Volume:
1.77
Capitalizzazione di mercato:
$48.05M
Reddito:
-
Utile/perdita netta:
$-34.77M
Rapporto P/E:
-1.686
EPS:
-3.3097
Flusso di cassa netto:
$-29.79M
1 W Prestazione:
+1.64%
1M Prestazione:
+4.01%
6M Prestazione:
-55.05%
1 anno Prestazione:
-57.72%
Intervallo 1D:
$5.24
$6.18
Intervallo di 1 settimana:
$5.162
$6.18
Portata 52W:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
5.58 | 48.05M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa
Atossa Genetics stock surges after FDA rare disease designation - Investing.com
Atossa Therapeutics (ATOS) Secures FDA Designation for Pediatric Treatment - GuruFocus
Atossa gets rare pediatric disease tag for endoxifen in MAS By Investing.com - Investing.com South Africa
FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone - Traders Union
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PR Newswire
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Aktiellt
Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum - Traders Union
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights - TipRanks
Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com - Investing.com South Africa
Atossa Therapeutics reaches settlement in Endoxifen patent dispute - Investing.com
Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight - Stock Titan
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union
ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union
Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS
ATOS Stock Eyes Fresh Highs Amid Strong Buying Pressure - Cổng thông tin điện tử Tỉnh Sơn La
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):